-
-
Merck Announces New Data Supporting Continued Use of MAVENCLAD (Cladribine Tablets) During the COVID-19 Pandemic
-
Posted in Industry News
-
06th May 2021
-
Mavenclad news from Merck
-
-
Real-world data in Parkinson’s disease patients with motor fluctuations assesses the clinical utility of Ongentys® (opicapone)
-
Posted in Industry News,Sponsored Feature
-
29th Apr 2021
-
Heinz Reichmann
-
-
NICE recommends Novartis’ Kesimpta®▼ (ofatumumab) for patients living with relapsing remitting multiple sclerosis (RRMS)
-
Posted in Industry News
-
21st Apr 2021
-
Industry news from Novartis
-
-
Stroke scholarships at UCL – 31st May deadline
-
Posted in Course & Conference Previews,Industry News
-
06th Apr 2021
-
* New deadline* Apply by 31st May
-
-
PCN-101 (R-ketamine) for depressive disorders
-
Posted in Industry News
-
02nd Apr 2021
-
News from Perception Neuroscience and Otsuka Pharmaceutical Co., Ltd
-
-
Novartis receives EU approval for Kesimpta® (ofatumumab), self-administered, targeted B-cell therapy for adult patients with relapsing MS
-
Posted in Industry News
-
01st Apr 2021
-
News from Novartis
-
-
Janssen Receives Positive CHMP Opinion for PONVORY™ ▼ (ponesimod) for RRMS
-
Posted in Industry News
-
29th Mar 2021
-
News from Janssen Pharmaceuticals
-
-
EPIDYOLEX® (cannabidiol) for treatment of seizures associated with Tuberous Sclerosis Complex
-
Posted in Industry News
-
03rd Mar 2021
-
News from GW Pharma
-
-
NeuroLifeNow App
-
Posted in Industry News
-
23rd Feb 2021
-
New App and website to support people with neurological conditions
-
-
BIAL takes the lead with Zebinix®
-
Posted in Industry News
-
18th Feb 2021
-
News from Bial regarding marketing and distribution of Zebinix®